A phase I trial of high dose gefitinib for patients with leptomeningeal metastases from non-small cell lung cancer

Oncotarget
David M JackmanSantosh Kesari

Abstract

There are few effective treatment options for leptomeningeal metastasis (LM) in non-small-cell lung cancer (NSCLC). This study assessed the feasibility of high-dose gefitinib in patients with LM from NSCLC harboring EGFR mutations or prior systemic response to EGFR-TKI. This phase I open-label trial of a novel gefitinib dosing schedule employed a 3+3 design. Eligible NSCLC patients with LM had known EGFR mutations and/or prior response to EGFR-TKI. Patients alternated 2 weeks of high-dose daily gefitinib (dose levels: 750 mg, 1000 mg, 1250 mg) with 2 weeks of maintenance therapy (500 mg daily). Primary endpoints were safety and toxicity. Secondary endpoints included overall survival (OS), neurological progression-free survival, radiological response, and cytological response in cerebrospinal fluid (CSF). Seven patients were treated: 3 at 750 mg dose level, 4 at 1000 mg dose level. There were no DLTs at the 750 mg dose level, and one DLT (toxic epidermal necrolysis) at the 1000 mg dose level. The study was closed due to slow accrual. Median neurological PFS was 2.3 months (range 1.6-4.0 months); median OS was 3.5 months (range 1.6-5.1 months). Though there were no radiologically documented remissions of LM disease, four patients...Continue Reading

References

Feb 1, 1974·Archives of Neurology·J R LittleH Okazaki
Mar 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S A GrossmanD S Ettinger
May 1, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Malcolm RansonEric K Rowinsky
Sep 14, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Roy S HerbstPatricia Mucci LoRusso
Mar 28, 2003·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Keiichi FujiwaraMitsune Tanimoto
May 16, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Masahiro FukuokaJosé Baselga
Nov 26, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jeremy N RichHenry S Friedman
Sep 1, 2004·Journal of the Neurological Sciences·Ulrich HerrlingerMichael Weller
Oct 12, 2004·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Katsuyuki HottaMitsune Tanimoto
Dec 2, 2004·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·W BoogerdCh J Vecht
Feb 26, 2005·Proceedings of the National Academy of Sciences of the United States of America·Jeffrey A EngelmanLewis C Cantley
Sep 20, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David M JackmanBruce E Johnson
Nov 7, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Marissa N BalakWilliam Pao
Aug 13, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·David M JackmanBruce E Johnson
Aug 21, 2009·The New England Journal of Medicine·Tony S MokMasahiro Fukuoka
Jun 25, 2010·The New England Journal of Medicine·Makoto MaemondoUNKNOWN North-East Japan Study Group
Sep 3, 2010·The Annals of Pharmacotherapy·Anthony J Perissinotti, David J Reeves

❮ Previous
Next ❯

Citations

Oct 7, 2015·Expert Opinion on Pharmacotherapy·Giulio MetroLucio Crinò
Feb 11, 2016·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Mostafa M GhorabMohammad K Parvez
Jul 12, 2016·International Journal of Molecular Sciences·Dae-Won LeeBhumsuk Keam
Nov 3, 2016·Current Opinion in Neurology·Emilie Le Rhun, Evanthia Galanis
Nov 23, 2017·Cancer·Nancy WangPriscilla K Brastianos
Mar 15, 2018·Therapeutic Advances in Neurological Disorders·Alessia PellerinoRiccardo Soffietti
Jan 25, 2018·Current Treatment Options in Oncology·Jerome J Graber, Santosh Kesari
Jul 12, 2018·Cancer Medicine·Wenting NiYin Lu
Dec 9, 2016·Science Translational Medicine·Zhenfan YangXiaolin Zhang
Apr 18, 2016·Current Treatment Options in Oncology·Nam BuiHatim Husain
Oct 27, 2017·Oncotarget·Gautam NayarPeter E Fecci
Dec 7, 2019·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·James C H YangMyung-Ju Ahn
Oct 26, 2018·Therapeutic Advances in Respiratory Disease·Biagio RicciutiRita Chiari
Jan 30, 2016·Targeted Oncology·Jan-Paul BohnMichael Steurer
Dec 2, 2017·Journal of Neuro-oncology·Mark T J van BusselDieta Brandsma
Feb 16, 2020·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Xi LiShucai Zhang
Dec 4, 2019·Indian Journal of Cancer·Shekar Patil, Krishna Kumar Rathnum
Jan 23, 2020·Neurología : publicación oficial de la Sociedad Española de Neurología·E García Molina, M Penas-Prado
Jul 1, 2017·Annals of Oncology : Official Journal of the European Society for Medical Oncology·E Le RhunUNKNOWN EANO Executive Board and ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org
Jan 3, 2018·Annals of Oncology : Official Journal of the European Society for Medical Oncology·G GossJ C-H Yang
Jul 27, 2021·Journal of Clinical Pharmacy and Therapeutics·Ding LiWenzhou Zhang
Jul 12, 2020·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Jiyun LeeMyung-Ju Ahn

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT00372515

Related Concepts

Related Feeds

CSF & Lymphatic System

This feed focuses on Cerebral Spinal Fluid (CSF) and the lymphatic system. Discover the latest papers using imaging techniques to track CSF outflow into the lymphatic system in animal models.